2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Wednesday, November 16, 2016

11:00AM-12:30PM: Abstract Number: 3241

Genetic Variation and Tobacco Smoke Exposure in Systemic Lupus Erythematosus: A Case Control Study Among African Americans

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3230

Genome-Wide Association Study Identifies Novel Sjögren’s Syndrome Risk Loci in the Regions of NAB1, TYK2, and PTTG1-mir146a

Sjögren's Syndrome II: Basic Insights

11:00AM-12:30PM: Abstract Number: 3242

Identification and Functional Characterization of TNIP1 Causal Variants Associated with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3200

Immunoscintigraphic Detection Of Tumor Necrosis Factor By Radiolabeled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis in Relation to Disease Activity: A Proof of Concept Study

Imaging of Rheumatic Diseases III: Crystal Arthritis, Osteoarthritis, Connective Tissue Disease and Vasculitis

11:00AM-12:30PM: Abstract Number: 3214

Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative

Rheumatoid Arthritis – Clinical Aspects VII: The Impact of Treating to Target

11:00AM-12:30PM: Abstract Number: 3249

Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3192

Influence of Temperature and Humidity on Disease Activity in Rheumatoid Arthritis

Health Services Research II

11:00AM-12:30PM: Abstract Number: 3216

Integrated High-Dimensional Analyses Reveal a Pathologically Expanded ‘Peripheral’ B Cell-Helper T Cell Population in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3198

Inter-Reader and Intra-Reader Reliability of the New Omeract Ultrasonographic Criteria for the Diagnosis of Calcium Pyrophosphate Deposition Disease

Imaging of Rheumatic Diseases III: Crystal Arthritis, Osteoarthritis, Connective Tissue Disease and Vasculitis

11:00AM-12:30PM: Abstract Number: 3240

Interferon Kappa Is a Novel Type I IFN That Drives Cutaneous Inflammation in Systemic Lupus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3243

Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 3193

Is an Intensive Diet and Exercise Regimen Cost-Effective for Obese and Overweight Patients with Symptomatic Knee OA?

Health Services Research II

11:00AM-12:30PM: Abstract Number: 3235

Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus: Up to 7 Years of Treatment Exposure

Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Quality of Life

11:00AM-12:30PM: Abstract Number: 3226

Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction

11:00AM-12:30PM: Abstract Number: 3253

Minimum Physical Function Needed to Walk 6000 Steps/Day in People with Knee Osteoarthritis

ARHP VI: Rehabilitation Sciences

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].